HER2/CEP17 ratio predicts residual cancer burden after neoadjuvant dual HER2 blockade: real-world data in patients with primary HER2-amplified breast cancer. - Stolz M; Farr A; Tendl-Schulz KA; Frommlet F; Reckendorfer H; Koperek O; Neudert B; Marhold M; Heber U; Exner R; Singer CF; Bartsch R; et al. (Virchows Archiv : an international journal of pathology, 2025)